– Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 – NEW YORK, Aug. 26, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its previously announced 1-for-15 reverse share split…


Previous articlePT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch For Nociplastic Pain
Next articlePsychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs